IOTA Pharmaceuticals

Email Usinfo@iotapharma.com

IOTA Pharmaceuticals
Fragment - based Drug Discovery
Neglected Parasitic Disease
Glioma & Glioblastoma
WINDOW on Glioblastoma
 
 
IOTA Pharmaceuticals
August 21, 2017
 

IOTA Scientists publish ACS Perspective on Fragment-Based Drug Discovery of Phosphodiesterase Inhibitors

IOTA scientists Dr David Bailey and Dr Fredrik Svensson, together with Dr Andreas Bender from the University of Cambridge, have published a Perspective in the Journal of Medicinal Chemistry reviewing the use of fragment-based drug discovery approaches for the production of phosphodiesterase inhibitors. Read the paper here.


Back
RSS